Ziopharm Oncology Names James Huang to Board of Directors
July 22, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech –– Managing Partner at Kleiner Perkins...
Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+ Leukemias and Lymphomas
July 09, 2020 16:15 ET
|
ZIOPHARM Oncology Inc
BOSTON, July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced the initiation of a phase 1 clinical trial to evaluate CD19-specific...
Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors
July 08, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
BOSTON, July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has...
Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma
June 22, 2020 08:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, June 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial...
Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board
June 15, 2020 08:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl...
Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020
June 12, 2020 09:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, June 12, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate...
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology
May 29, 2020 08:00 ET
|
ZIOPHARM Oncology Inc
– Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile – – Controlled IL-12 in combination with PD-1...
Ziopharm Oncology Announces Management Transition
May 27, 2020 16:15 ET
|
ZIOPHARM Oncology Inc
BOSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced Dr. David Mauney is stepping down as President. Dr. Mauney remains a...
Ziopharm Oncology to Present at the Jefferies 2020 Healthcare Conference on June 3, 2020
May 27, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
BOSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate...
Ziopharm Oncology to Present at the BofA Securities 2020 Health Care Conference
May 08, 2020 09:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual...